Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) Titrate-To-Target: An Observational Study of the Efficacy of NovoLog® Mix 70/30 in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets on OADs With / Without Once Daily Basal Insulin Therapy

NCT00791895 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00791895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00791895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) Titrate-To-Target: An Observational Study of the Efficacy of NovoLog® Mix 70/30 in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets on OADs With / Without Once Daily Basal Insulin Therapy
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
June 26, 2003
Completion date
November 29, 2004
Enrollment
102 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2